Obesity
Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug
Nordisk, Obesity, Approved, Oral cavity, Glucagon-Like Peptide 1, Market, Pressure- physical agent, eli lilly, competition, Novo, semaglutide, United States Food and Drug Administration, United States Food and Drug Administration
Pfizer’s Strategic Shift Post-Danuglipron: Exploring New Frontiers in Obesity Treatment
Pfizer, danuglipron, obesity treatment, GLP-1 receptor agonist, liver injury, weight-loss drugs, GLP-1/GIP therapies, pharmaceutical competition, metabolic diseases, Viking Therapeutics, obesity pipeline
Novo Nordisk Invests $1.1 Billion to Expand GLP-1 Drug Manufacturing in Brazil
Novo Nordisk , GLP-1 production , Brazil investment , Wegovy and Ozempic , Diabetes treatment , Obesity treatment , Montes Claros facility , Pharmaceutical manufacturing
Drug pricing watchdog ICER offers ways to increase obesity drug access
ICER, Obesity, Access, Wegovy, Policy, drug price
Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B
Obesity, LX9851, lexicon, Mechanism (attribute)
Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks
Novo Nordisk, UBT251, obesity treatment, triple agonist, weight loss, GLP-1, GIP, glucagon, The United Laboratories International Holdings Limited
GLP-1 Players Seek to Differentiate in Increasingly Crowded Weight Loss Space
GLP-1 drugs, weight loss market, differentiation, competition, obesity treatment
Roche expands obesity pipeline, paying Zealand Pharma $1.65B upfront to codevelop amylin asset
This deal represents a major expansion of Roche’s obesity drug pipeline and a significant partnership in the competitive weight loss medication market.
Viking Signs $150M Manufacturing Agreement with CordenPharma for Obesity Drug Candidate
Viking Therapeutics, CordenPharma, VK2735, obesity drug, manufacturing agreement, GLP-1/GIP dual agonist
Viking Therapeutics Signs $150 Million Manufacturing Deal with CordenPharma for Obesity Drug VK2735
Viking Therapeutics, CordenPharma, VK2735, Obesity drug, GLP-1/GIP dual agonist, Contract manufacturing, API production, Fill/finish capacity, Subcutaneous and oral formulations